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Abstract 
Background 
Clozapine is widely underused.  No study has assessed views of patients suitable for, but not 
yet receiving, clozapine.  We aimed to assess views of clozapine in patients eligible for 
clozapine but not yet prescribed it. 
Methods 
Semi-structured interviews with acutely unwell hospital inpatients. 
Main Results 
We interviewed 61 of 116 eligible patients and 50 (82%) answered all questions.  At 
interview, 33 of 61 participants (54%) had heard of clozapine and 17 of 57 (30%) said they 
would take it if asked.  Overall, 31 of 54 (57%) respondents said blood testing would not 
preclude them taking clozapine.  The necessity for hospital admission was seen as the 
greatest barrier to receiving clozapine – 25 of 51 respondents (49%) stated this would be a 
reason for their refusing clozapine.  Concerns about adverse effects of clozapine were 
considered sufficient to refuse clozapine in 23 of 53 (43.4%) respondents.  Overall, 12 of 50 
(24%) respondents felt that clozapine would be helpful to them. 
 
Principal Conclusions 
Patients’ acceptance of clozapine is likely to be improved by offering the opportunity to 
start clozapine at home and by improved education about the therapeutic benefits of 
clozapine and the management of its adverse effects.  Blood testing does not appear to be 
an important barrier to the initiation of clozapine. 
Keywords: clozapine, compliance, concordance, patient views 
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Introduction 
Despite the established unique efficacy of clozapine in treatment-resistant schizophrenia, it 
remains under-prescribed (Howes et al., 2012).  The reasons for this are not clear but 
perhaps are most likely to lie at the interface of the patient and prescriber. We have 
previously shown that the barriers psychiatry practitioners cited as most frequently 
preventing clozapine prescription are: patient refusal of regular blood testing; patient 
refusal of baseline blood testing; patient concerns about tolerability; medical complications; 
patient refusal of hospital admission; and the patient being unsure of efficacy (Gee et al., 
2013). If one excludes co-morbid medical complications, the top five reasons that 
practitioners report for not prescribing clozapine are patient-related. This is at odds with 
research examining patient opinions of clozapine in which experiences expressed are 
overwhelming positive, with tolerability and the need for blood tests considered to be major 
problems far less frequently by patients than by clinicians (Taylor et al., 2000). However, 
there is a significant bias in that the rather limited available literature is confined to the 
opinions of patients who are already taking clozapine.  By definition this cohort of patients 
will have consented to treatment and remained compliant with it. Surveys of existing 
patients could be said to confirm only what might otherwise be assumed.  Therefore, in this 
study we surveyed the perhaps more relevant views of those patients who were eligible for, 
but not currently prescribed, clozapine, with the intention to better understand the patient-
related barriers to clozapine initiation.  
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Method 
The survey of patient attitudes to clozapine was approved by the trust’s Drug and 
Therapeutics Committee.  Patients admitted to three acute psychiatric wards at the Bethlem 
Royal Hospital in London, UK in 2015 and 2016 were considered for inclusion in the study.  
Demographic details and compliance with eligibility criteria were gathered from clinical 
notes. 
Eligibility criteria were: 
- Admission to an acute ward at the Bethlem Royal Hospital 
- Prescription of two or more antipsychotics over the course of the illness (up to and 
including the current prescription), each for at least 6 weeks and at a minimum 
effective dose 
- Diagnosis of schizophrenia or schizoaffective disorder 
- No previous trials of clozapine 
Patients were approached for inclusion in the survey by the lead investigator (SG), and if 
consent was given then a face-to-face questionnaire administered (also by SG).  Patients 
were first asked whether or not they had heard of clozapine.  If they answered “no” then a 
brief paragraph detailing the indication for clozapine (an antipsychotic, used to treat the 
symptoms of schizophrenia described as a reduction in hallucinations, improvement in 
concentration and thinking), common side effects (constipation, drowsiness, 
hypersalivation, dizziness on standing, tachycardia) and rare side effects (a reduction in 
white blood cells) was read to them.  They were fully informed of the need for blood testing 
and its frequency, and also that some people found clozapine to be the only medication 
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effective for them.  This paragraph was also read to patients who replied that they had 
already heard of clozapine, if it became clear later in the interview that there were aspects 
of the treatment that they were either not aware of, or did not understand fully.   
Participants were then asked whether they had ever been asked to take clozapine, and if so 
what the outcome was.  They were asked whether they would consider taking clozapine 
now, were it to be offered to them. 
Likert scales were used to assess patients’ opinions on the need for baseline blood tests, 
regular blood tests, side effects, and the potential need for hospital admission to initiate 
clozapine.  Written descriptions were used to present the possible options, which ranged 
from ‘0’ (that doesn’t bother/worry me at all, ‘1’ (I’d be slightly bothered/worried but I’d 
still be willing to try it), ‘2’ (I’d be fairly bothered/worried but I’d still be willing to try it), ‘3’ 
(I’d be very bothered/worried but I’d still be willing to try it) to ‘4’ (I wouldn’t try clozapine 
because of this/the side effects).  Participants were also asked whether starting clozapine at 
home would be preferable to being admitted to hospital in order to titrate the dose. 
Finally, participants were asked to compare, as far as they were able, clozapine with 
medicines they had taken in the past, or were taking currently, and to rate how much they 
thought clozapine would help them.  A Likert scale was again used to gather responses, 
ranging from ‘0’ (clozapine would be a lot less helpful than other medicines I’ve had), ‘1’ 
(clozapine would be slightly less helpful than other medicines I’ve had), ‘2’ (clozapine would 
be about the same as other medicines I’ve had), ‘3’ (clozapine would be a bit better than 
other medicines I’ve had), to ‘4’ (clozapine would be a lot better than other medicines I’ve 
had’).  Where possible, their reasons for their answers were also noted. 
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Patients who fully or partially completed the questionnaire were designated ‘participants’, 
and patients who refused to take part, or could not be interviewed for other reasons were 
designated ‘non-participants’.  Independent t-tests for continuous variables and Pearson’s 
chi-squared test for categorical variables were used to compare the demographics of 
patients in the participating and non-participating groups.  All data were analysed using 
SPSS version 22.  A copy of the questionnaire is available on request from the authors. 
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Results 
In total, 468 patients admitted to the wards were assessed for entry into the study.  Of 
these, 116 fulfilled the eligibility criteria for the study and of these 25% (29 of 116 patients) 
refused to take part, 5% (6 of 116 patients) were considered too unwell to provide informed 
consent, 10% (12 of 116 patients) were discharged before an interview could take place, and 
7% (8 of 116 patients) were excluded for other reasons (predominantly a lack of sufficient 
English or transfer to another hospital before interview).  The remaining 61 patients were 
considered ‘participants’ in the survey, and of these 82% (50 of 61 patients) answered all 
the questions asked, with a further 18% (11 of 61 patients) answering at least 1 question. 
 
Demographics 
Table 1 goes here  
 
Questionnaire results  
Just over half of the patients surveyed had heard of clozapine (54%, 33 of 61 patients), and a 
fifth (19%, 11 of 57 patients) recalled being asked to consider taking it as a treatment for 
their illness.  
 
Table 2 goes here 
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A larger proportion of participants reported that if asked to take clozapine now, they would 
refuse (35%, 20 of 57 patients) although this was a narrow majority, with 30% (17 of 57 
patients) saying that they would be willing to try it. 
 
Table 3 goes here 
 
Of those seventeen subjects that said they would take clozapine if it were offered to them 
now, fourteen provided further explanation.  The most frequent theme (5 patients) that 
emerged was that the patient wanted their mental health to improve, and felt that 
clozapine would be helpful in this way: 
 
“I want my mental health to recover” 
“I need something in addition to my current medicines” 
 
The next most common statements (4 patients) were related to trust in the opinion of the 
professionals caring for them: 
“If it would help I’d take it.  I trust the doctor’s opinion – if they say I need it then I’ll 
take it” 
“I know it would do me good.  I trust you.” 
 
For patients who stated that they would not take clozapine, might take it or were not sure if 
they would take it if it were offered to them, 38 provided a more detailed response.  The 
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most commonly cited reason (15 patients) for either refusing clozapine or being unsure 
about treatment was related to the side effects or blood monitoring, and of these most 
responses focussed on the effects on the white blood cells or the blood monitoring in some 
way (8 patients):  
 
“There are more negatives than positives… the side effects” 
“The constant monitoring.  The side effects – salivation, drowsiness.  I don’t like 
needles.” 
 “It kills white blood cells” 
“The white cell thing sounds risky” 
 
Other common themes included not believing that any medication was necessary at the 
moment (5 patients), being happy with the current medication (4 patients) and being 
unsure what the effects of clozapine might be (3 patients). 
 
Table 4 goes here 
 
When asked how they felt about having blood taken before starting clozapine, a narrow 
majority of participants (35%, 19 of 54 patients) reported that this wouldn’t bother them at 
all.  The opposite answer, ‘I wouldn’t try clozapine because of this’ was the next most 
common response (32%, 17 of 54 patients).  Proportionally more patients reported that 
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regular blood tests would put them off trying clozapine (41%, 22 of 54 patients), with 28% 
(15 of 54 patients) stating that this wouldn’t bother them at all.  The side effects of 
clozapine were a barrier to clozapine for a substantial proportion of patients, with 43% (23 
of 53 patients) saying that this would put them off clozapine entirely and 19% (10 of 53 
patients) reporting that the side effects would worry them very much.  In contrast, 17% (9 of 
53 patients) said the side effects didn’t worry them at all, and 15% (8 of 53 patients) said 
they would be slightly worried.  When asked how they would feel about coming into 
hospital in order to initiate clozapine, the largest proportion of patients (49%, 25 of 51 
patients) said this would put them off trying clozapine.  However, a significant proportion 
(29%, 15 of 51 patients) reported that being admitted in order to start clozapine wouldn’t 
bother them at all.  
 
Figure 1 goes here 
 
When asked which side effects particularly worried them, 30 patients gave more detailed 
answers.  Of these, the most common side effect cited was dizziness or any cardiac 
complication (8 patients), followed by the effects on white blood cells (6 patients).  Some 
patients expressed beliefs they held about the medicine both in general and in relation to 
side effects: 
“I see other patients that drool, it means you are disabled.” 
“The strength of the pill makes me worried about collapsing.  You can’t miss a day of 
taking clozapine, so you are basically dependent on it.” 
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Others weighed the balance of side effects against the potential benefits: 
“Medicines are there to improve and stay positive so I’m not worried about side 
effects.” 
“I know other people who take clozapine.  For them the psychosis is so bad the side 
effects are worth taking.  It’s a balance for each individual.  Therefore if I needed 
clozapine I wouldn’t care about the side effects because I would need it.” 
“I've had drooling on amisulpride before, so I wouldn't want this to happen again.  I 
don't need clozapine.  But I recognise that if psychosis is really bad then people need 
clozapine and then for them any negative problems (having to have bloods done, the 
side effects, being admitted) are outweighed by the benefits.  So the problem is 
people not having any insight into the severity of their psychosis.” 
 
A clear majority of participants (67%, 34 of 51 patients) felt that starting clozapine at home 
would be better than being admitted to hospital, although a significant proportion (26%, 13 
of 51 patients) disagreed (4 (8%) did not give an opinion). 
 
Comments made by patients who stated that they would rather come into hospital to start a 
medicine than be at home included: 
“I would be worried about starting clozapine at home because side effects wouldn’t 
be monitored.” 
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“A professional should be starting medicines so it is better to be in hospital for this, 
not at home.” 
“If you feel ill it’s better to come into hospital for medicines to be started because 
that’s where the doctors are – it’s better to be with them.” 
 
When asked to compare the likely effect of clozapine to other medicines they had taken, the 
majority of patients (32%, 16 of 50 patients) felt that it would be “a lot less helpful” for 
them, 3 (6%) felt it would be slightly less helpful, and 6 (12%) felt it would be “about the 
same”.  Twelve participants (24%) thought clozapine would be “a bit better” (7, 14%) or “a 
lot better” (5, 10%).  The second most common answer was “I don’t know” (20%, 10 of 50 
patients).  Three participants’ answers could not be classified.   
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Discussion 
This study aimed to evaluate and categorise the opinions of potential clozapine patients on 
clozapine initiation, side effects and its potential effectiveness.  The patients included were 
specifically selected as those who were not taking, and had not ever taken clozapine 
previously, and who were also acutely unwell.  This group of patients were considered to 
reflect most accurately those that clinicians might expect to treat in daily practice and for 
whom clozapine might be considered the treatment of choice. 
 
A significant proportion of patients (46%) reported that they had never heard of clozapine, 
and 70% said they had never been asked to take it.  We did not interrogate the clinical notes 
to establish whether this was the case, and arguably patients cannot be expected to recall 
all medicines that have been discussed with them in the past, but the lack of awareness by 
patients of the drug is striking and perhaps explains the low prescription rates of clozapine 
in our Trust (Howes, et al., 2012).  Conversely, this lack of familiarity may be seen as 
encouraging, as patients do not necessarily enter into a conversation about clozapine with 
preconceived ideas about its benefits or disadvantages.  Further to this, 46% of patients 
stated that they would either take clozapine were it to be offered to them, or that they 
were unsure.  A minority (35%) rejected the idea outright. 
 
We have previously found that clinicians consider patients’ refusal to undergo blood tests to 
be the main barrier to prescribing of clozapine (Gee, et al., 2013).  In the present study, a 
high degree of concern was expressed by some patients about this, with 36% of participants 
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stating that blood tests would put them off trying clozapine.  However, this proportion does 
not represent the majority – the remainder felt that the blood tests presented no worry at 
all (31%) or that they would be worried only to some extent, but still willing to try clozapine 
(30%).  Thus for 61% of patients eligible for clozapine blood testing was not a barrier to its 
use. 
 
Also in our previous study, clinicians felt that the next most worrying aspect of clozapine 
therapy for patients was overall tolerability.  We found 43% of patients to be unwilling to try 
clozapine because of adverse effects, although again the majority were either not worried at 
all, or worried but still open to considering treatment (53%). 
 
When considering hospital admission as a barrier to patients willingly accepting clozapine 
treatment, 49% of patients stated that this would mean they would not want to try the 
medication.  Of the remaining patients, almost a third (29%) did not feel this was a concern 
at all, and this was further reflected in a similar percentage actively wishing to be in hospital 
rather than at home to start clozapine (26%).  Thus the main barrier to using clozapine is not 
blood testing but the apparent necessity to be admitted to start clozapine.  
 
Finally, patients do not appear to consider clozapine to be as effective as the available data 
suggest it is, with 38% thinking it would be less helpful than other medicines they have 
previous taken, or were taking at the time of the study, just 24% thinking it would be better, 
and 12% considering it to be about the same.  It is possible that patients were taking into 
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account the burden of side effects, hospital admission and blood monitoring when 
answering this question – and this perhaps makes it all the more relevant.  Nonetheless, 
educating patients about the potential benefits of clozapine is likely to prove beneficial in 
the attempt to get more people on to clozapine. 
 
To our knowledge, this is the first study to evaluate opinions about clozapine of patients 
who are not taking the drug, but who, in accordance with local and national guidelines 
(National Institute for Health and Clinical Excellence, 2010; Taylor et al., 2015), should be.  
Other authors have described the attitudes of patients who have already been established 
on clozapine, and these are overwhelmingly positive.  Patients were repeatedly found not to 
mind the blood monitoring (Taylor, et al., 2000; Wolfson & Paton, 1996), to prefer clozapine 
to their previous medications (Waserman & Criollo, 2000; Wolfson & Paton, 1996), and to 
find it generally helpful for them when compared to other medicines – even when they 
were considered to lack insight into their condition (Castle et al., 2002).  These studies 
cannot be said to represent the views of patients who are not taking clozapine, and 
therefore cannot help to address the issue of chronic under prescribing of the medication. 
 
Our results do not show that patients are universally against the idea of clozapine, but that 
concerns about hospital admission, adverse effects and, to a lesser extent, blood monitoring 
are important.  These concerns do not apply to every patient however, and patients vary in 
the degree to which they express concern about these aspects of treatment.  It is clear that 
there is a need to increase patient awareness of the benefits of clozapine.  We found in our 
survey that almost half of patients who would be considered eligible for clozapine treatment 
16 
 
had never heard of it, let alone knew anything about it.  Clinicians should therefore be 
mindful not to assume that patients have prior knowledge of clozapine (either in terms of 
benefits or drawbacks).  Rettenbacher et al. (Rettenbacher et al., 2004) found that patients 
with schizophrenia usually estimated other chronic diseases to be considerably worse than 
theirs, and so the authors suggested that patients might not take their illness seriously 
enough to consider taking medication to treat it.  Regular discussions with healthcare 
professionals about schizophrenia and its treatment course with patients may improve this 
attitude, potentially increasing familiarity with clozapine and decreasing what might be 
considered a detrimental ‘fear of the unknown’.  It may also be beneficial to move away 
from the practice of introducing the idea of an entirely new medication with unique 
monitoring requirements and side effects at the point of acute psychotic relapse.  Instead, 
the treatment pathway for schizophrenia should be made transparent and clear to patients 
from the outset of illness.  This may make easier initiating clozapine at a time of severe 
illness. 
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Limitations 
Our study included only a small number of patients from a single hospital and so our 
findings may or may not be generalizable to patients in other units or countries.  It is almost 
important to be aware that patient views, expressed in the abstract (in response to a 
questionnaire) may differ markedly from actions and opinions taken in reality.   
 
It is vitally important that clinicians are aware of the views of patients regarding medication 
in chronic conditions, such as schizophrenia, as it provides the basis of the appropriate 
approach necessary to overcome the sometimes considerable obstacles to prescribing 
clozapine effectively.  We have shown that awareness of clozapine amongst patients was 
generally low, especially considering that these patients would be eligible for clozapine 
treatment on the basis of their clinical record.  Patients were largely unaware of the clinical 
benefits of clozapine. There is a need for increased patient awareness of the role of 
clozapine, and this may include initiatives such as the use of patient advocates to educate 
fellow patients about medication, and services supporting the initiation of clozapine at 
home. 
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Table 1. Demographic and participation details 
 Total 
cohort, 
n = 116 
Participants, 
n = 61 
Non-
participants, 
n = 55 
P 
Mean age, years (range) 43  
(19 - 76) 
42  
(20 – 71) 
44  
(19 – 76) 
0.31 
Gender, male (%) 84 (72) 48 (79) 36 (66) 0.05 
Ethnicity, n (%) White 31 (27) 18 (30) 13 (24) 0.08 
Black 62 (53) 31 (51) 31 (56) 
Asian 12 (10) 4 (7) 8 (15) 
Mixed or other 11 (9) 8 (13) 3 (5) 
Mean days between admission and 
interview (range) 
13  
(0 – 68) 
11 (0 – 61) 15 (1 – 68) 0.21 
Diagnosis, n (%) Schizophrenia 88 (76) 45 (74) 43 (78) 0.15 
Schizoaffective 
disorder 
28 (24) 16 (26) 12 (22) 
Interview outcome, n 
(%) 
Fully answered 61 (53) 
Refused 29 (25) 
Unwell 6 (5) 
Discharged 12 (10) 
Other 8 (7) 
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Table 2. Responses to ‘Have you heard of a medication called clozapine?’ 
 
Table 3. Responses to ‘If you were asked to take clozapine now, how would you respond?’ 
 N  (%) 
If you were asked to take 
clozapine now, how would you 
respond? 
I’d take it 17 (30) 
I wouldn’t take it 20 (35) 
I might take it 2 (4) 
Don’t know 7 (12) 
Other 1 (2) 
 
  
 N Yes,  
n (%) 
No,  
n (%) 
Don’t know,  
n (%) 
Have you heard of clozapine? 61 33 (54) 26 (43) 2 (3) 
Have you ever been asked to take clozapine? 57 11 (19) 40 (70) 6 (11) 
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Table 4. Responses to Likert scale-measured questions 
  That doesn’t 
bother/worry 
me at all 
I’d be slightly 
bothered/worried 
but would still try 
clozapine 
I’d be fairly 
bothered/worried 
but would still try 
clozapine 
I’d be very 
bothered/worried 
but would still try 
clozapine 
I wouldn’t 
try 
clozapine 
because 
of this 
Don’t 
know 
Other 
N  N (%) N (%) N (%) N (%) N (%) N 
(%) 
N 
(%) 
How would 
you feel 
about having 
blood taken 
before 
starting 
clozapine? 
54 19 (35) 6 (11) 5 (9) 5 (9) 17 (32) 1 (2) 1 (2) 
How would 
you feel 
about having 
blood taken 
regularly 
whilst taking 
clozapine? 
54 15 (28) 5 (9) 4 (7) 7 (13) 22 (41) 0 (0) 1 (2) 
How much 
do the side 
effects of 
clozapine 
worry you? 
53 9 (17) 8 (15) 1 (2) 10 (19) 23 (43) 2 (4) 0 (0) 
How would 
you feel 
about being 
admitted to 
hospital in 
order to start 
clozapine? 
51 15 (29) 0 (0) 7 (14) 3 (6) 25 (49) 0 (0) 1 (1) 
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Figure 1 Responses to questionnaire, shown as percentage of responses for each question 
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